BERKELEY, Calif. and MAINZ, Germany — August 13, 2025 — Leads & Copy — Mainz Biomed N.V. (NASDAQ:MYNZ) announced that its ColoAlert® colorectal cancer (CRC) screening test has been approved in Switzerland by Swissmedic. The non-invasive test is now authorized for use in the Swiss market and will be available through Mainz Biomed’s partner laboratory, labor team w ag.
CRC screening in Switzerland focuses on individuals aged 50-74, who account for approximately 31.4% of the country’s population. Despite existing screening programs, participation rates remain below 50%. Mainz Biomed believes that innovative tests like ColoAlert can improve participation rates and support national health goals.
ColoAlert is designed to detect CRC tumor DNA and other biomarkers in stool samples. Mainz Biomed continues to expand ColoAlert’s reach through partnerships with laboratories and healthcare providers.
“We are pleased to receive regulatory approval in Switzerland,” said Guido Baechler, CEO of Mainz Biomed.
Contact:
Maximilian Schur / Simone Neeten
+49 211 529252 20
mainzbiomed@mc-services.eu
Source: Mainz Biomed
